LPL Financial LLC Purchases 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• LPL Financial LLC increased its stake in Regeneron Pharmaceuticals by 1.4%, holding a total of 55,245 shares valued at approximately $35 million as of the end of the first quarter.
• Regeneron Pharmaceuticals recently declared a quarterly dividend of $0.88 per share, which translates to an annualized yield of 0.6% and a payout ratio of 8.96%.
• Analysts have cut their price targets for Regeneron Pharmaceuticals, with Goldman Sachs lowering its target from $917 to $804, indicating a cautious outlook despite maintaining a "buy" rating.

LPL Financial LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,245 shares of the biopharmaceutical company's stock after purchasing an additional 755 shares during the quarter. LPL Financial LLC owned about 0.05% of Regeneron Pharmaceuticals worth $35,038,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after purchasing an additional 303,785 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Regeneron Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $837.61.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $13.41 during trading on Friday, hitting $558.87. The company had a trading volume of 1,656,418 shares, compared to its average volume of 941,817. The company has a fifty day moving average price of $538.05 and a two-hundred day moving average price of $603.39. The company has a current ratio of 5.39, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $60.34 billion, a P/E ratio of 14.08, a P/E/G ratio of 2.10 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.